Seasonal affective disorder (SAD): pathophysiology, risk factors, and evidence-based management during seasonal shifts

Seasonal affective disorder (SAD) is a subtype of major depressive disorder in which depressive symptoms follow a seasonal pattern, most commonly emerging in autumn or winter and improving during spring or summer. The seed for this topic is the phrase “seizoenskaart” (seasonal card), reflecting the concept that mood changes can be seasonal rather than solely situational. Clinically, SAD is characterized by recurrent episodes, a temporal relationship to seasonal cues, and symptom clusters that overlap with other depressive disorders.

Epidemiology and clinical presentation vary by latitude, photoperiod, and individual vulnerability. SAD is reported more frequently in higher latitudes where winter daylight is reduced. Core symptoms include persistent low mood, anhedonia, hypersomnia (often pronounced in winter-onset SAD), increased appetite with carbohydrate craving, fatigue, psychomotor slowing, and impaired concentration. Anxiety may co-occur, and some individuals experience irritability or social withdrawal. The seasonal nature is key: episodes typically remit during the opposite season, distinguishing SAD from non-seasonal depression where symptom timing is not consistently seasonal.

A central mechanistic model involves circadian rhythm disruption and photic signaling. Reduced daylight affects retinal input to the suprachiasmatic nucleus, the brain’s master circadian pacemaker. This can lead to misalignment between internal biological rhythms and the external light–dark cycle. Circadian misalignment can alter sleep architecture, endocrine rhythms (including melatonin suppression dynamics and cortisol timing), and downstream neurotransmitter regulation. In turn, altered serotonergic activity, changes in dopamine-related reward processing, and stress-axis dysregulation may contribute to depressive symptoms.

Neurobiological findings support a multifactorial basis. Serotonin pathways are implicated because seasonal changes may influence synaptic availability and receptor sensitivity. Melatonin dysregulation and phase delays or advances may worsen mood by destabilizing sleep timing and circadian amplitude. Additionally, photoperiod-dependent immune and inflammatory signaling has been proposed; winter-related immune shifts may interact with neural plasticity and sickness-behavior circuits. Genetic susceptibility is also relevant: first-degree relatives of individuals with major depressive disorder have higher risk, and polymorphisms affecting circadian genes or neurotransmitter systems may increase vulnerability.

Risk factors include residence at higher latitudes, female sex in many cohorts (though men are not exempt), early-onset mood disorders, family history of depression, bipolar disorder risk screening, and existing circadian sleep problems. A history of depression or subthreshold depressive symptoms that track seasons increases the likelihood of diagnosing SAD rather than transient mood variability. It is also important to differentiate SAD from other entities: winter blues can be milder and do not meet full DSM criteria, whereas bipolar depression must be ruled out because antidepressant monotherapy can precipitate manic or hypomanic episodes.

Evidence-based treatment commonly begins with light therapy. Bright light exposure—typically in the morning—aims to shift circadian timing and improve retinal-driven biological rhythm stability. Protocols vary, but many clinical regimens use a bright light box with distance and duration tailored to symptom severity and eye-safety guidance. Response rates are often substantial, and benefits can appear within days to weeks. Clinicians should consider contraindications or precautions such as photosensitivity disorders, certain ocular diseases, or concurrent medications that increase light sensitivity.

Psychotherapy is another core option, particularly cognitive-behavioral therapy (CBT) adapted for SAD. CBT targets maladaptive cognitions related to seasonal helplessness, behavioral withdrawal, and avoidance, and it can include behavioral activation to counter winter lethargy and anhedonia. Sleep-focused strategies and circadian hygiene can complement therapy by reinforcing consistent wake times and exposure to natural light when feasible.

Pharmacologic management may be indicated for moderate to severe SAD, incomplete response to light therapy, or when symptoms significantly impair functioning. Selective serotonin reuptake inhibitors (SSRIs) have evidence in seasonal depression, and some guidelines support prophylactic initiation at the appropriate time before symptom onset for patients with recurrent patterns. Any antidepressant plan should include screening for bipolar spectrum symptoms and careful monitoring for activation or mood switching.

Lifestyle interventions can support recovery and relapse prevention. Regular physical activity, especially outdoors during daylight hours, can enhance circadian entrainment and improve mood via neurotrophic and anti-inflammatory effects. Dietary considerations may address winter appetite changes and carbohydrate cravings. Stress management and social engagement can reduce the cognitive spiral of seasonal demoralization.

Prognosis is often favorable when the seasonal pattern is recognized and treatment is timely. Because SAD episodes tend to recur, long-term management typically integrates a prevention strategy: early light therapy, planned behavioral activation, and—when appropriate—scheduled medication initiation. Patients benefit from psychoeducation that symptoms are not a sign of personal failure but a predictable interaction between biology and seasonal environmental cues. Recognizing and treating SAD transforms uncertainty into a structured, evidence-based plan.

Source: @Tweet2Tijn